No evidence of disease activity after fingolimod treatment: A three-year real-world comparison of pre- and post-treatment outcomes in multiple sclerosis
Key Points
No evidence of disease activity is observed after three years of fingolimod treatment.
The study compares outcomes before and after treatment in a real-world setting over three years.
Analysis includes assessments of disease activity metrics among multiple sclerosis patients.
These findings highlight the potential effectiveness of fingolimod in managing multiple sclerosis.
No evidence of disease activity after fingolimod treatment: A three-year real-world comparison of pre- and post-treatment outcomes in multiple sclerosis | Synapse